Report: Vermont Trust Company Increases Stake in Altria Group

Aug.07.2024
Report: Vermont Trust Company Increases Stake in Altria Group
According to a report by DAILY POLITICAL on August 6, Vermont Trust Company increased its holdings in Altria Group.

According to a report from DAILY POLITICAL on August 6th, Vermont Trust company disclosed in its latest report to the U.S. Securities and Exchange Commission (SEC) that it increased its holdings of Altria Group (Altria Group, Inc., NYSE: MO) by 0.8% in the second quarter.


During the period, the company purchased an additional 320 shares, bringing their total holdings of the company's stock to 42,091 shares. As of the end of the most recent quarter, the Vermont Trust Company's stake in Altria Group was valued at $1,917,000.


Other large investors have also made changes to their holdings in the company. Maryland Capital Advisors Inc. increased its stake in Altria Group by 154.4% in the first quarter. Now, Maryland Capital Advisors Inc. owns 575 shares of the company, worth $25,000, after acquiring an additional 349 shares.


Accordant Advisory Group Inc purchased new shares of Altria Group in the first quarter valued at approximately $26,000.


In the first quarter, BNP Paribas of France acquired shares of Altria Group worth around $27,000, while Westend Capital Management LLC purchased shares of Altria Group valued at approximately $29,000.


Finally, Criterion Capital Advisors LLC purchased new shares of Altria Group in the fourth quarter, worth approximately $27,000. Institutional investors and hedge funds own 57.41% of the company's shares.


Wall Street analysts' views on Altria Group stock.


Multiple research companies recently shared their views on Altria Group. Stifel Nicolaus, in a report on Thursday, August 1, raised Altria Group's target price from $50.00 to $54.00 and assigned a "buy" rating to the company. UBS Group, in a report on Monday, April 8, raised Altria Group's target price from $36.10 to $36.50 and assigned a "sell" rating to the company.


In its report on Wednesday, July 10th, Bank of America raised Altria Group's target price from $47.00 to $48.00 and gave the company a "neutral" rating. Argus upgraded Altria Group's rating to "hold" in its report on Friday, May 31st.


Finally, StockNews.com upgraded Altria Group's rating from "hold" to "buy" in a report issued on Friday, June 28th. One analyst gave the stock a sell rating, three analysts gave it a hold rating, and three analysts issued buy ratings. According to MarketBeat.com data, the current consensus rating for the stock is "hold" with a consensus target price of $47.90.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Bringing Tax and Insurance Into Nicotine Regulation: Insights From a Tobacco Harm-Reduction Report
Bringing Tax and Insurance Into Nicotine Regulation: Insights From a Tobacco Harm-Reduction Report
A smoke-free nicotine policy report argues that tobacco harm reduction should move beyond product bans and health warnings into tax policy, insurance pricing and risk-based regulation. While some projections remain open to debate, the report highlights a wider challenge: nicotine products, technologies and consumer behavior have changed sharply over the past decade, and regulatory systems may need new tools to better align tobacco control with harm-reduction goals.
Jun.08
Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million
Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million
Ispire Technology reported financial results on May 7, 2026, for the third quarter of fiscal 2026, covering the three months ended March 31, 2026. Revenue was $18.7 million, compared with $26.2 million in the third quarter of fiscal 2025 and $20.3 million in the prior quarter. Gross profit was $2.0 million, with gross margin of 10.7%. Net loss was $9.5 million, or $0.17 per share. The company said it held $18.0 million in cash as of March 31, 2026, up $468,000 sequentially.
May.08 by 2FIRSTS.ai
 NYT: Reynolds American Donated $5 Million Before FDA Vape Policy Shift
NYT: Reynolds American Donated $5 Million Before FDA Vape Policy Shift
According to The New York Times, Reynolds American donated $5 million to a Trump-backed super PAC shortly before the FDA introduced a new policy that could benefit major tobacco companies seeking to sell flavored vaping products.
News
May.21
Product|PMI Expands High-Strength Nicotine Pouch Portfolio With Zyn 16.5mg
Product|PMI Expands High-Strength Nicotine Pouch Portfolio With Zyn 16.5mg
According to Better Retailing, Philip Morris International (PMI) has launched Zyn Menthol Ice 16.5mg in the UK, marking the highest-strength nicotine pouch in the Zyn range to date. The eucalyptus- and menthol-flavored product is now available through PMI Open and will begin rolling out to wholesale channels from the end of May.
PMI
May.28
State Registries Are Reshaping U.S. Vape Market Access 2Firsts Interview with U.S. Vapor Manufacturers Association President Allison Boughner
State Registries Are Reshaping U.S. Vape Market Access 2Firsts Interview with U.S. Vapor Manufacturers Association President Allison Boughner
As the U.S. vapor market faces FDA authorizations, import seizures and growing state-level restrictions, AVM President Allison Boughner told 2Firsts that state product registries and white-list systems are having the most immediate impact. She said distributors are placing greater weight on documentation, product origin and supply-chain transparency.
Special Report
May.26
PML Expands Its UK Smoke-Free Portfolio With LEVIA
PML Expands Its UK Smoke-Free Portfolio With LEVIA
Philip Morris Limited has launched LEVIA, a new range of zero-tobacco flavored nicotine sticks created for the IQOS ILUMA range. The product expands the company’s smoke-free portfolio in the UK and will initially be available in four variants, including Deep Mint and three capsule-based flavors. LEVIA has a recommended retail price of £5, or about $6.73, based on the European Central Bank’s April 28.
Apr.29 by 2FIRSTS.ai